公开(公告)号：US20250034272A1

公开(公告)日：2025-01-30

申请号：US18739089

申请日：2024-06-10

Applicant: Equillium, Inc.

Inventor： Stephen CONNELLY ,  Cherie NG

IPC: C07K16/28 ,  A61K31/137 ,  A61K31/46 ,  A61K31/573 ,  A61P11/06

Abstract: The present disclosure provides compositions and methods related to treating, ameliorating, and preventing asthma, and in particular steroid resistant or refractory severe asthma, with an anti-CD6 antibody, or an antigen binding portion thereof, alone or in combination with other agents useful in treating asthma.

公开(公告)号：US20240053360A1

公开(公告)日：2024-02-15

申请号：US18265121

申请日：2021-12-03

Applicant: Equillium, Inc.

Inventor： Stephen CONNELLY ,  Jeanette AMPUDIA ,  Nhu (Dalena) Ngo CHU ,  Cherie T. NG

IPC: G01N33/68 ,  G01N33/569 ,  G01N33/564

CPC classification number: G01N33/6872 ,  G01N33/56972 ,  G01N33/564 ,  G01N2333/70596 ,  G01N2500/04 ,  G01N2500/10 ,  G01N2800/245

Abstract: Provided are methods and compositions comprising anti-CD6 antibodies, such as itolizumab, which selectively target CD6high T cells, for example, to reduce levels of cell surface CD6 on such cells, decrease the overall levels and pathogenic activity of CD6high T cells or the ratio of CD6high:CD6low T cells in a subject or ex vivo, decrease the overall levels and pathogenic activity of Teff cells or the ratio of Teff:Treg cells in a subject or ex vivo, and/or increase generation of Treg cells in a subject or ex vivo, and thereby modulate a pathogenic immune response in the subject, among other aspects.

公开(公告)号：US20220143140A1

公开(公告)日：2022-05-12

申请号：US17434247

申请日：2020-02-26

Applicant: Equillium, Inc. ,  University of Houston System

Inventor： Stephen Connelly ,  Krishna Polu ,  Chandra Mohan

IPC: A61K38/17 ,  G01N33/68 ,  A61P37/00 ,  A61K31/573 ,  A61K31/675 ,  A61K31/5377

Abstract: The present disclosure provides methods of treating inflammatory or autoimmune diseases (e.g., lupus nephritis) using CD6-ALCAM pathway inhibitors such as EQ001 and to methods and diagnostic tests for identifying subjects likely to respond to such inhibitors. In particular, the present disclosure provides diagnostic and therapeutic uses related to elevated levels of soluble ALCAM and/or CD6 protein and protein fragments in urine and other biological samples that are indicative of sensitivity to inhibitors of the CD6-ALCAM pathway (e.g., EQ001).

公开(公告)号：US20210380711A1

公开(公告)日：2021-12-09

申请号：US16976298

申请日：2019-02-27

Applicant: Equillium, Inc.

Inventor： Stephen CONNELLY ,  Cherie NG

IPC: C07K16/28 ,  A61K31/137 ,  A61K31/573 ,  A61K31/46 ,  A61P11/06

Abstract: The disclosure provides compositions and methods related to treating, ameliorating, and preventing asthma, and in particular steroid resistant or refractory severe asthma, with an anti-CD6 antibody, itolizumab, or an antigen binding portion thereof, alone or in combination with other agents useful in treating asthma.